{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:55:44Z","timestamp":1792454144301,"version":"4.5.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2018.01167","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T23:28:37Z","timestamp":1547767717000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":142,"title":["Diagnostic and Prognostic Performance of Neurofilaments in ALS"],"prefix":"10.3389","volume":"9","author":[{"given":"Koen","family":"Poesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17085","DOI":"10.1038\/nrdp.2017.85","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.clinph.2007.09.143","article-title":"Electrodiagnostic criteria for diagnosis of ALS","volume":"119","author":"de Carvalho","year":"2008","journal-title":"Clin Neurophysiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ana.22380","article-title":"Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study","volume":"70","author":"Schrooten","year":"2011","journal-title":"Ann Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3109\/21678421.2014.903974","article-title":"Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS)","volume":"15","author":"Paganoni","year":"2014","journal-title":"Amyotr Lateral Scler Frontotem Degener."},{"key":"B6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1474-4422(18)30089-9","article-title":"Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model","volume":"17","author":"Westeneng","year":"2018","journal-title":"Lancet Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S1474-4422(08)70293-X","article-title":"Biomarkers in amyotrophic lateral sclerosis","volume":"8","author":"Turner","year":"2009","journal-title":"Lancet Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","article-title":"Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases","volume":"91","author":"Bacioglu","year":"2016","journal-title":"Neuron"},{"key":"B9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1146\/annurev.ne.19.030196.001155","article-title":"Neuronal intermediate filaments","volume":"19","author":"Lee","year":"1996","journal-title":"Ann Rev Neurosci."},{"key":"B10","first-page":"4","article-title":"Neurofilaments and neurofilament proteins in health and disease","volume-title":"Cold Spring Harbor Perspect Biol.","author":"Yuan","year":"2017"},{"key":"B11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2147\/TACG.S69969","article-title":"The genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and management","volume":"8","author":"Hoyle","year":"2015","journal-title":"Appl Clin Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/hmg\/3.10.1757","article-title":"Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis","volume":"3","author":"Figlewicz","year":"1994","journal-title":"Hum Mol Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0092-8674(01)00244-6","article-title":"Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded","volume":"104","author":"Julien","year":"2001","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/00005072-198409000-00002","article-title":"Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis","volume":"43","author":"Hirano","year":"1984","journal-title":"J Neuropathol Exp Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/jnen\/59.11.972","article-title":"Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS)","volume":"59","author":"Wong","year":"2000","journal-title":"J Neuropathol Exp Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1097\/00005072-199910000-00009","article-title":"Extra neurofilament NF-L subunits rescue motor neuron disease caused by overexpression of the human NF-H gene in mice","volume":"58","author":"Meier","year":"1999","journal-title":"J Neuropathol Exp Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"9631","DOI":"10.1073\/pnas.95.16.9631","article-title":"Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant","volume":"95","author":"Williamson","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"key":"B18","doi-asserted-by":"publisher","first-page":"9626","DOI":"10.1073\/pnas.95.16.9626","article-title":"Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase","volume":"95","author":"Couillard-Despres","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e40998","DOI":"10.1371\/journal.pone.0040998","article-title":"Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS","volume":"7","author":"Lu","year":"2012","journal-title":"PLoS ONE"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/j.1471-4159.2009.06386.x","article-title":"Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker","volume":"111","author":"Boylan","year":"2009","journal-title":"J Neurochem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13195-018-0339-1","article-title":"A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation","volume":"10","author":"Gaetani","year":"2018","journal-title":"Alzheimers Res Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jim.2013.11.008","article-title":"The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA","volume":"402","author":"Koel-Simmelink","year":"2014","journal-title":"J Immunol Methods"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1212\/WNL.0000000000004029","article-title":"Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease","volume":"88","author":"Poesen","year":"2017","journal-title":"Neurology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1471-4159.2011.07224.x","article-title":"Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS","volume":"117","author":"Ganesalingam","year":"2011","journal-title":"J Neurochem"},{"key":"B25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0022-1759(03)00189-3","article-title":"A specific ELISA for measuring neurofilament heavy chain phosphoforms","volume":"278","author":"Petzold","year":"2003","journal-title":"J Immunol Methods"},{"key":"B26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jim.2006.09.021","article-title":"Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain","volume":"319","author":"Petzold","year":"2007","journal-title":"J Immunol Methods"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.bbrc.2005.08.252","article-title":"Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury","volume":"336","author":"Shaw","year":"2005","journal-title":"Biochem Biophys Res Commun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/15368590252917647","article-title":"Monoclonal antibodies selective for low molecular weight neurofilaments","volume":"21","author":"Norgren","year":"2002","journal-title":"Hybridoma Hybridom."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin Chem Lab Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/jnnp-2015-311387","article-title":"Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients","volume":"87","author":"Steinacker","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1212\/WNL.0000000000004761","article-title":"Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis","volume":"90","author":"Feneberg","year":"2018","journal-title":"Neurology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3389\/fneur.2018.00726","article-title":"Diagnostic performance of neurofilaments in chinese patients with amyotrophic lateral sclerosis: a prospective study","volume":"9","author":"Li","year":"2018","journal-title":"Front Neurol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318704","article-title":"Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis","author":"Verde","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12511","article-title":"Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis","author":"Gille","year":"2018","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00415-009-0131-z","article-title":"CSF neurofilament protein analysis in the differential diagnosis of ALS","volume":"256","author":"Reijn","year":"2009","journal-title":"J Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0165-5728(87)90048-8","article-title":"Varying degrees of phosphorylation determine microheterogeneity of the heavy neurofilament polypeptide (Nf-H)","volume":"14","author":"Goldstein","year":"1987","journal-title":"J Neuroimmunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1212\/01.wnl.0000203120.85850.54","article-title":"Axonal damage markers in cerebrospinal fluid are increased in ALS","volume":"66","author":"Brettschneider","year":"2006","journal-title":"Neurology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jneuroim.2010.01.004","article-title":"A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein","volume":"220","author":"Kuhle","year":"2010","journal-title":"J Neuroimmunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1136\/jnnp-2017-316605","article-title":"Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis","volume":"89","author":"De Schaepdryver","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ana.24552","article-title":"Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis","volume":"79","author":"Weydt","year":"2016","journal-title":"Ann Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1046\/j.1471-4159.1996.67052013.x","article-title":"Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF","volume":"67","author":"Rosengren","year":"1996","journal-title":"J Neurochem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0164625","DOI":"10.1371\/journal.pone.0164625","article-title":"Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"11","author":"Xu","year":"2016","journal-title":"PLoS ONE"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/j.1468-1331.2007.01972.x","article-title":"Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype","volume":"14","author":"Zetterberg","year":"2007","journal-title":"Eur J Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e75091","DOI":"10.1371\/journal.pone.0075091","article-title":"Increased neurofilament light chain blood levels in neurodegenerative neurological diseases","volume":"8","author":"Gaiottino","year":"2013","journal-title":"PLoS ONE"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","article-title":"Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"Lu","year":"2015","journal-title":"Neurology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/j.1468-1331.2012.03777.x","article-title":"Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression","volume":"19","author":"Tortelli","year":"2012","journal-title":"Eur J Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ene.12421","article-title":"Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis","volume":"22","author":"Tortelli","year":"2015","journal-title":"Eur J Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/acn3.212","article-title":"CSF neurofilament light chain reflects corticospinal tract degeneration in ALS","volume":"2","author":"Menke","year":"2015","journal-title":"Ann Clin Trans Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3109\/21678421.2016.1167913","article-title":"Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS","volume":"17","author":"Oeckl","year":"2016","journal-title":"Amyotr Later Scler Frontotemp Degen."},{"key":"B50","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2012-303768","article-title":"Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"Boylan","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ana.24980","article-title":"Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis","volume":"82","author":"Gendron","year":"2017","journal-title":"Ann Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3109\/21678421.2014.884592","article-title":"Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis","volume":"15","author":"Lehnert","year":"2014","journal-title":"Amyotr Later Scler Frontotemp Degen."},{"key":"B53","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jns.2015.04.032","article-title":"Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis","volume":"353","author":"McCombe","year":"2015","journal-title":"J Neurol Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jns.2016.05.062","article-title":"Phosphorylated neurofilament heavy chain levels in paired plasma and CSF of amyotrophic lateral sclerosis","volume":"367","author":"Li","year":"2016","journal-title":"J Neurol Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12883-016-0689-x","article-title":"Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis","volume":"16","author":"Chen","year":"2016","journal-title":"BMC Neurol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1021\/acs.jproteome.7b00660","article-title":"Comparison of internal standard approaches for SRM analysis of alpha-synuclein in cerebrospinal fluid","volume":"17","author":"Oeckl","year":"2018","journal-title":"J Proteome Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1373\/clinchem.2013.220392","article-title":"Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid","volume":"60","author":"Leinenbach","year":"2014","journal-title":"Clin Chem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1515\/cclm-2018-0147","article-title":"Commutability of the certified reference materials for the standardization of beta-amyloid 1\u201342 assay in human cerebrospinal fluid: lessons for tau and beta-amyloid 1\u201340 measurements","volume":"56","author":"Andreasson","year":"2018","journal-title":"Clin Chem Lab Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/2472630317750378","article-title":"Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays","volume":"23","author":"Gille","year":"2018","journal-title":"SLAS Technol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ana.25276","article-title":"Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion","volume":"84","author":"Benatar","year":"2018","journal-title":"Ann Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jamaneurol.2016.5398","article-title":"Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease","volume":"74","author":"Gaiani","year":"2017","journal-title":"JAMA Neurol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1212\/WNL.0b013e31824e8f53","article-title":"Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV","volume":"78","author":"Chio","year":"2012","journal-title":"Neurology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1212\/WNL.0b013e31828f18ac","article-title":"Cognitive changes predict functional decline in ALS: a population-based longitudinal study","volume":"80","author":"Elamin","year":"2013","journal-title":"Neurology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e1619","DOI":"10.1212\/WNL.0000000000006383","article-title":"CSF sAPPbeta, YKL-40, and NfL along the ALS-FTD spectrum","volume":"91","author":"Illan-Gala","year":"2018","journal-title":"Neurology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/JCI99081","article-title":"Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J Clin Invest."},{"key":"B66","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1136\/jnnp-2014-307672","article-title":"Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study","volume":"86","author":"Lu","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2018.01167\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T23:28:40Z","timestamp":1547767720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2018.01167\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":67,"alternative-id":["10.3389\/fneur.2018.01167"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2018.01167","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"article-number":"1167"}}